123I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M1 In Vivo

Geor Bakker; Wilhelmina A. Vingerhoets; Jan–Peter van Wieringen; Kora de Bruin; Jos Eersels; Jan de Jong; Youssef Chahid; Bart P. Rutten; Susan DuBois; Megan Watson; Adrian J. Mogg; Hongling Xiao; Michael Crabtree; David A. Collier; Christian C. Felder; Vanessa N. Barth; Lisa M. Broad; Oswald J. Bloemen; Thérèse A. van Amelsvoort; Jan Booij

doi:10.2967/jnumed.114.147488

Research ArticleBasic Science Investigations

¹²³I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M₁ In Vivo

Geor Bakker, Wilhelmina A. Vingerhoets, Jan–Peter van Wieringen, Kora de Bruin, Jos Eersels, Jan de Jong, Youssef Chahid, Bart P. Rutten, Susan DuBois, Megan Watson, Adrian J. Mogg, Hongling Xiao, Michael Crabtree, David A. Collier, Christian C. Felder, Vanessa N. Barth, Lisa M. Broad, Oswald J. Bloemen, Thérèse A. van Amelsvoort and Jan Booij

Journal of Nuclear Medicine February 2015, 56 (2) 317-322; DOI: https://doi.org/10.2967/jnumed.114.147488

Geor Bakker

1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wilhelmina A. Vingerhoets

1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jan–Peter van Wieringen

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kora de Bruin

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jos Eersels

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jan de Jong

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Youssef Chahid

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bart P. Rutten

1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Susan DuBois

3Eli Lilly and Co., Indianapolis, Indiana; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Megan Watson

3Eli Lilly and Co., Indianapolis, Indiana; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Adrian J. Mogg

4Lilly Research Centre, Eli Lilly and Co., Windlesham, Surrey, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Hongling Xiao

3Eli Lilly and Co., Indianapolis, Indiana; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Crabtree

4Lilly Research Centre, Eli Lilly and Co., Windlesham, Surrey, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David A. Collier

4Lilly Research Centre, Eli Lilly and Co., Windlesham, Surrey, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian C. Felder

3Eli Lilly and Co., Indianapolis, Indiana; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vanessa N. Barth

3Eli Lilly and Co., Indianapolis, Indiana; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lisa M. Broad

4Lilly Research Centre, Eli Lilly and Co., Windlesham, Surrey, United Kingdom

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Oswald J. Bloemen

1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thérèse A. van Amelsvoort

1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jan Booij

2Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 56, Issue 2

February 1, 2015

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 123I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M1 In Vivo

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

¹²³I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M₁ In Vivo

Journal of Nuclear Medicine Feb 2015, 56 (2) 317-322; DOI: 10.2967/jnumed.114.147488

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

¹²³I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M₁ In Vivo

Journal of Nuclear Medicine Feb 2015, 56 (2) 317-322; DOI: 10.2967/jnumed.114.147488

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography

Google Scholar

Keywords

Dexetimide
muscarinic receptors
cognition
SPECT imaging
Characterization

Main menu

User menu

Search

¹²³I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M₁ In Vivo

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords